This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apex Affinity Selects Elsevier's Gold Standard Drug Database

TAMPA, Florida, May 20, 2013 /PRNewswire/ --

Elsevier will provide Apex with essential drug information in a streamlined database solution

Elsevier, a world-leading provider of scientific, medical and technical information products and services, today announced an agreement with Apex Affinity, provider of innovative prescription discount programs for uninsured and underinsured families nationwide. Apex has selected Elsevier's Gold Standard Drug Database for providing current and accurate drug content to enhance its member products, including a new consumer drug reference portal.

Apex leverages the purchasing power of millions of consumers to negotiate deep discounts on brand-name and generic prescriptions at nearly all major big box stores, drug store chains and independent neighborhood pharmacies. Apex will use Elsevier's Gold Standard Drug Database to enable members to compare drug pricing, look-up accurate dosage information, and learn about alternative therapies and what a medication is used for and what it does.

"With the Gold Standard Drug Database, we can provide our members with the most up-to-date drug information in an easy to use format," said Scott Paul, Apex's Chief Executive Officer. "It will help our members make informed decisions about their medications and their health."

The Gold Standard Drug Database content is updated daily and has a peer-reviewed editorial process in place to ensure the highest accuracy of drug product information, drug pricing and patient education information. Apex will benefit from the database's modern technical architecture and flexible implementation, which distinguishes Gold Standard Drug Database from other drug databases.

"With the implementation of our Gold Standard Drug Database, Apex will have the confidence that their value-added consumer reference products contain superior drug information that allows their members to swiftly and effortlessly research their medications," said Trygve Anderson, R.Ph.

Vice President of Product Management, Elsevier's Gold Standard.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs